LEGISLATURE OF NEBRASKA

ONE HUNDREDTH LEGISLATURE

SECOND SESSION

LEGISLATIVE BILL 830

FINAL READING

Introduced by Lathrop, 12; Gay, 14.

Read first time January 10, 2008

Committee: Health and Human Services

A BILL

1	FOR AN	ACT relating to public health and welfare; to amend
2		section 68-901, Revised Statutes Cumulative Supplement,
3		2006, and section 71-7611, Revised Statutes Supplement,
4		2007, as amended by section 2, Legislative Bill 480, One
5		Hundredth Legislature, Second Session, 2008, and section
6		5, Legislative Bill 961, One Hundredth Legislature,
7		Second Session, 2008; to adopt the Medicaid Prescription
8		Drug Act; to harmonize provisions; to change provisions
9		relating to use of the Nebraska Health Care Cash Fund;
10		and to repeal the original sections.

11 Be it enacted by the people of the State of Nebraska,

-1-

	LB 830 LB 830
1	Section 1. Section 68-901, Revised Statutes Cumulative
2	Supplement, 2006, is amended to read:
3	68-901 Sections 68-901 to 68-949 and sections 2 to 8 of
4	this act shall be known and may be cited as the Medical Assistance
5	Act.
6	Sec. 2. Sections 2 to 8 of this act shall be known and
7	may be cited as the Medicaid Prescription Drug Act.
8	Sec. 3. The purpose of the Medicaid Prescription
9	Drug Act is to provide appropriate pharmaceutical care to
10	medicaid recipients in a cost-effective manner by requiring the
11	establishment of a preferred drug list and other activities as
12	prescribed. The preferred drug list and other activities mandated
13	by the act shall not be construed to replace, prohibit, or
14	limit other lawful activities of the department not specifically
15	permitted or required by the act.
16	Sec. 4. For purposes of the Medicaid Prescription Drug
17	Act:
18	(1) Labeler means a person or entity that repackages
19	prescription drugs for retail sale and has a labeler code from the
20	federal Food and Drug Administration under 21 C.F.R. 207.20, as
21	such regulation existed on January 1, 2008;
22	(2) Manufacturer means a manufacturer of prescription
23	drugs as defined in 42 U.S.C. 1396r-8(k)(5), as such section
24	existed on January 1, 2008, including a subsidiary or affiliate of
25	such manufacturer;

-2-

1	(3) Multistate purchasing pool means an entity formed
2	by an agreement between two or more states to negotiate for
3	supplemental rebates on prescription drugs;
4	(4) Pharmacy benefit manager means a person or entity
5	that negotiates prescription drug price and rebate arrangements
6	with manufacturers or labelers;
7	(5) Preferred drug list means a list of prescription
8	drugs that may be prescribed for medicaid recipients without prior
9	authorization by the department; and
10	(6) Prescription drug has the definition found in section
11	<u>38-2841.</u>
12	Sec. 5. (1) No later than July 1, 2010, the department
13	shall establish and maintain a preferred drug list for the medical
14	assistance program. The department shall establish a pharmaceutical
15	and therapeutics committee to advise the department on all matters
16	relating to the establishment and maintenance of such list.
17	(2) The pharmaceutical and therapeutics committee shall
18	include at least fifteen but no more than twenty members. The
19	committee shall consist of at least (a) eight physicians, (b) four
20	pharmacists, (c) a university professor of pharmacy or a person
21	with a doctoral degree in pharmacology, and (d) two public members.
22	No more than twenty-five percent of the committee shall be state
23	employees.
24	(3) The physician members of the committee, so far as

25 practicable, shall include physicians practicing in the areas

-3-

of (a) family medicine, (b) internal medicine, (c) pediatrics, 1 2 (d) cardiology, (e) psychiatry or neurology, (f) obstetrics or 3 gynecology, (g) endocrinology, and (h) oncology. 4 (4) Members of the committee shall submit conflict of 5 interest disclosure statements to the department and shall have an 6 ongoing duty to disclose conflicts of interest not included in the 7 original disclosure. 8 (5) The committee shall elect a chairperson and a vice 9 chairperson from among its members. Members of the committee shall 10 be reimbursed for their actual and necessary expenses as provided 11 in sections 81-1174 to 81-1177. 12 (6) The department, in consultation with the committee, 13 shall adopt and publish policies and procedures relating to the 14 preferred drug list, including (a) guidelines for the presentation 15 and review of drugs for inclusion on the preferred drug list, 16 (b) the manner and frequency of audits of the preferred drug list 17 for appropriateness of patient care and cost effectiveness, (c) 18 an appeals process for the resolution of disputes, and (d) such 19 other policies and procedures as the department deems necessary and 20 appropriate. 21 Sec. 6. (1) The department and the pharmaceutical and 22 therapeutics committee shall consider all therapeutic classes of 23 prescription drugs for inclusion on the preferred drug list, except 24 that antidepressant, antipsychotic, and anticonvulsant prescription 25 drugs shall not be subject to consideration for inclusion on the

1 preferred drug list.

2	(2) (a) The department shall include a prescription
3	drug on the preferred drug list if the prescription drug is
4	therapeutically equivalent to or superior to a prescription drug on
5	the list and the net cost of the new prescription drug is equal to
6	or less than the net cost of the listed drug, after consideration
7	of applicable rebates or discounts negotiated by the department.
8	(b) If the department finds that two or more prescription
9	drugs under consideration for inclusion on the preferred drug list
10	are therapeutically equivalent, the department shall include the
11	more cost-effective prescription drug or drugs on the preferred
12	drug list, after consideration of applicable rebates or discounts
13	negotiated by the department.
14	(3) The department shall maintain an updated preferred
15	drug list in electronic format and shall make the list available to
16	the public on the department's Internet web site.
17	Sec. 7. <u>(1) A health care provider may prescribe a</u>
18	prescription drug not on the preferred drug list to a medicaid
19	recipient if (a) the prescription drug is medically necessary,
20	(b)(i) the provider certifies that the preferred drug has not
21	been therapeutically effective, or with reasonable certainty is
22	not expected to be therapeutically effective, in treating the
23	recipient's condition or (ii) the preferred drug causes or is
24	reasonably expected to cause adverse or harmful reactions in
25	the recipient, and (c) the department authorizes coverage for

the prescription drug prior to the dispensing of the drug. The
 department shall respond to a prior authorization request no later
 than twenty-four hours after receiving such request.

(2) A health care provider may prescribe a prescription 4 drug not on the preferred drug list to a medicaid recipient 5 without prior authorization by the department if the provider 6 7 certifies that (a) the recipient is achieving therapeutic success 8 with a course of antidepressant, antipsychotic, or anticonvulsant 9 medication or medication for human immunodeficiency virus, multiple 10 sclerosis, epilepsy, cancer, or immunosuppressant therapy or (b) 11 the recipient has experienced a prior therapeutic failure with a 12 medication.

Sec. 8. The department shall: (1) Enter into a multistate purchasing pool; (2) negotiate directly with manufacturers or labelers; or (3) contract with a pharmacy benefit manager for negotiated discounts or rebates for all prescription drugs under the medical assistance program in order to achieve the lowest available price for such drugs under such program.

Sec. 9. Section 71-7611, Revised Statutes Supplement,
2007, as amended by section 2, Legislative Bill 480, One Hundredth
Legislature, Second Session, 2008, and section 5, Legislative Bill
961, One Hundredth Legislature, Second Session, 2008, is amended to
read:

24 71-7611 (1) The Nebraska Health Care Cash Fund is
25 created. The State Treasurer shall transfer (a) fifty-six million

-6-

LB 830

four hundred thousand dollars no later than July 30, 2008, and 1 2 (b) fifty-five million seven hundred thousand dollars annually 3 thereafter no later than July 15 from the Nebraska Medicaid Intergovernmental Trust Fund and the Nebraska Tobacco Settlement 4 5 Trust Fund to the Nebraska Health Care Cash Fund, except that such amount shall be reduced by the amount of the unobligated 6 7 balance in the Nebraska Health Care Cash Fund at the time the 8 transfer is made. On or before May 1, 2008, the State Treasurer 9 shall transfer from the Nebraska Medicaid Intergovernmental Trust 10 Fund and the Nebraska Tobacco Settlement Trust Fund an additional 11 two hundred fifty thousand dollars to the Nebraska Health Care 12 Cash Fund. The state investment officer upon consultation with 13 the Nebraska Investment Council shall advise the State Treasurer on the amounts to be transferred from the Nebraska Medicaid 14 15 Intergovernmental Trust Fund and from the Nebraska Tobacco 16 Settlement Trust Fund under this section in order to sustain such 17 transfers in perpetuity. The state investment officer shall report 18 to the Legislature on or before October 1 of every even-numbered 19 year on the sustainability of such transfers. Except as otherwise 20 provided by law, no more than fifty-five million seven hundred 21 thousand dollars the amount specified in subdivisions (1)(a) and 22 (b) of this subsection may be appropriated or transferred from the Nebraska Health Care Cash Fund in any fiscal year. 23

(2) Any money in the Nebraska Health Care Cash Fund
available for investment shall be invested by the state investment

-7-

LB 830

officer pursuant to the Nebraska Capital Expansion Act and the
 Nebraska State Funds Investment Act.

3 (3) One million dollars in the Nebraska Health Care Cash Fund is designated each year for the Autism Treatment Program 4 5 Act for five fiscal years beginning in fiscal year 2007-08 and shall be distributed in each fiscal year as follows: (a) First, 6 7 to the Department of Health and Human Services for costs related 8 to application and implementation of the waiver; (b) second, to 9 the department for other medical costs for children who would 10 not otherwise qualify for medicaid except for the waiver; and (c) 11 third, the balance to the Autism Treatment Program Cash Fund. The 12 State Treasurer shall transfer the balance of the funding to the 13 Autism Treatment Program Cash Fund based on the estimated costs 14 of administrative and other medical costs as determined by the 15 Legislature through the appropriation process. The transfers to the Autism Treatment Program Cash Fund in any fiscal year shall 16 17 be contingent upon the receipt of private matching funds under 18 the Autism Treatment Program Act, with no less than one dollar of private funds received for every two dollars transferred from the 19 20 Nebraska Health Care Cash Fund to the Autism Treatment Program Cash 21 Fund.

(4) The University of Nebraska and postsecondary educational institutions having colleges of medicine in Nebraska and their affiliated research hospitals in Nebraska, as a condition of receiving any funds appropriated or transferred from the

-8-

LB 830

Nebraska Health Care Cash Fund, shall not discriminate against any
 person on the basis of sexual orientation.

3 (5) The State Treasurer shall transfer two hundred 4 thousand dollars from the Nebraska Health Care Cash Fund to the 5 University of Nebraska Medical Center Cash Fund for the Nebraska 6 Regional Poison Center within fifteen days after each July 1.

Sec. 10. Original section 68-901, Revised Statutes
Cumulative Supplement, 2006, and section 71-7611, Revised Statutes
Supplement, 2007, as amended by section 2, Legislative Bill 480,
One Hundredth Legislature, Second Session, 2008, and section 5,
Legislative Bill 961, One Hundredth Legislature, Second Session,
2008, are repealed.